BG106046A - Pharmaceutical compositions of ertythropoietin - Google Patents

Pharmaceutical compositions of ertythropoietin

Info

Publication number
BG106046A
BG106046A BG106046A BG10604601A BG106046A BG 106046 A BG106046 A BG 106046A BG 106046 A BG106046 A BG 106046A BG 10604601 A BG10604601 A BG 10604601A BG 106046 A BG106046 A BG 106046A
Authority
BG
Bulgaria
Prior art keywords
ertythropoietin
pharmaceutical compositions
erythropoietin
amino acid
pharmaceutical formulations
Prior art date
Application number
BG106046A
Other languages
Bulgarian (bg)
English (en)
Inventor
Wing Cheung
Jaya Natarajan
Marilyn Sanders
Els Vercammen
Selima Begum
Basant Sharma
Original Assignee
Ortho-Mcneil Pharmaceutical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho-Mcneil Pharmaceutical, Inc. filed Critical Ortho-Mcneil Pharmaceutical, Inc.
Publication of BG106046A publication Critical patent/BG106046A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1816Erythropoietin [EPO]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG106046A 1999-04-09 2001-10-24 Pharmaceutical compositions of ertythropoietin BG106046A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12859699P 1999-04-09 1999-04-09
US09/545,479 US6696056B1 (en) 1999-04-09 2000-04-07 Pharmaceutical compositions of erythropoietin
PCT/US2000/009414 WO2000061169A1 (fr) 1999-04-09 2000-04-07 Composition pharmaceutique d'erythropoietine

Publications (1)

Publication Number Publication Date
BG106046A true BG106046A (en) 2002-05-31

Family

ID=22436082

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106046A BG106046A (en) 1999-04-09 2001-10-24 Pharmaceutical compositions of ertythropoietin

Country Status (27)

Country Link
US (2) US6696056B1 (fr)
EP (1) EP1181036B1 (fr)
JP (1) JP2002541208A (fr)
KR (1) KR100740794B1 (fr)
CN (1) CN1165339C (fr)
AR (1) AR029623A1 (fr)
AT (1) ATE401908T1 (fr)
AU (1) AU775041B2 (fr)
BG (1) BG106046A (fr)
BR (1) BR0010665A (fr)
CA (1) CA2369444C (fr)
CY (1) CY1108418T1 (fr)
DE (1) DE60039598D1 (fr)
DK (1) DK1181036T3 (fr)
ES (1) ES2308978T3 (fr)
HK (1) HK1041445B (fr)
HU (1) HUP0201068A3 (fr)
IL (1) IL145816A0 (fr)
MX (1) MXPA01010208A (fr)
NO (1) NO20014893L (fr)
NZ (1) NZ515380A (fr)
PL (1) PL203797B1 (fr)
PT (1) PT1181036E (fr)
RU (1) RU2225221C2 (fr)
TR (1) TR200103788T2 (fr)
WO (1) WO2000061169A1 (fr)
ZA (1) ZA200109236B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7304150B1 (en) 1998-10-23 2007-12-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
CA2369444C (fr) * 1999-04-09 2009-08-18 Ortho-Mcneil Pharmaceutical, Inc. Composition pharmaceutique d'erythropoietine
US7371787B2 (en) * 2000-04-14 2008-05-13 Viance, Llc Methods of incorporating treatment agents into wood based composite products
ME00673B (fr) * 2000-05-15 2011-12-20 Hoffmann La Roche Nouvelle composition pharmaceutique
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
EP1641486B1 (fr) 2003-06-10 2012-04-18 LG Life Sciences Ltd. Solutions aqueuses stables d'erythropoietine humaine ne contenant pas d'albumine serique
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
RU2006113593A (ru) * 2003-09-23 2006-08-27 Алькон, Инк. (Ch) Препаративные формы триамцинолона ацетонида и анекортава ацетата для инъекций
US7141544B2 (en) * 2003-10-10 2006-11-28 Baxter International, Inc. Stabilization of pharmaceutical protein formulations with small peptides
DE202004020676U1 (de) * 2004-03-10 2005-11-10 Bioceuticals Arzneimittel Ag Erythropoietin-Flüssigformulierung
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
US20050255112A1 (en) * 2004-05-17 2005-11-17 Lee Jong Y Compositions and methods for preventing erythropoietin-associated hypertension
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
WO2006020580A2 (fr) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Variants de polypeptides synthetiques hyperglycosyles resistants a la protease, formulations orales et leurs procedes d'utilisation
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
AU2006295340B2 (en) 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
CN101015684B (zh) * 2006-02-10 2011-08-24 华北制药集团新药研究开发有限责任公司 一种重组人红细胞生成素溶液制剂
US20080050749A1 (en) * 2006-08-17 2008-02-28 Ildiko Amann-Zalan Use of bnp-type peptides for the stratification of therapy with erythropoietic stimulating agents
US8796206B2 (en) * 2007-11-15 2014-08-05 Amgen Inc. Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
KR100956431B1 (ko) 2007-12-07 2010-05-06 주식회사 제이에스마루 혈장크린접착제 및 이의 제조방법
BR122012024318A2 (pt) 2008-09-26 2019-07-30 Ambrx, Inc. Polipeptídeos modificados de eritropoetina animal e seus usos
PE20150964A1 (es) 2012-09-07 2015-07-25 Coherus Biosciences Inc Formulaciones acuosas estables de adalimumab
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
PT3528787T (pt) 2016-10-21 2026-03-11 Amgen Inc Formulações farmacêuticas e métodos para produzir as mesmas
AU2018281334A1 (en) 2017-06-06 2019-12-19 Kindred Biosciences, Inc. Erythropoietin and analogs for veterinary use
CN111150837B (zh) * 2020-02-11 2022-07-12 中国人民解放军陆军军医大学 Epo在抗金黄色葡萄球菌感染药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6191131A (ja) * 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
DK173067B1 (da) * 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
GB8822857D0 (en) 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
GB9001987D0 (en) * 1990-01-29 1990-03-28 Janssen Pharmaceutica Nv Improved cyclodextrin based erythropietin formulation
GB9007052D0 (en) * 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
US5543575A (en) * 1990-06-20 1996-08-06 Pioneer-Hi-Bred International, Inc. Inbred corn line PHK46
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
DE4126984A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, gut vertraeglichen arzneimitteln fuer infusions- oder injektionszwecke
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
TW518219B (en) * 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
TW586933B (en) 1996-06-20 2004-05-11 Chugai Pharmaceutical Co Ltd Compositions for treating liver-complaints using EPO
CA2369444C (fr) * 1999-04-09 2009-08-18 Ortho-Mcneil Pharmaceutical, Inc. Composition pharmaceutique d'erythropoietine

Also Published As

Publication number Publication date
RU2225221C2 (ru) 2004-03-10
NZ515380A (en) 2003-10-31
KR100740794B1 (ko) 2007-07-20
PT1181036E (pt) 2008-10-03
TR200103788T2 (tr) 2002-05-21
DE60039598D1 (de) 2008-09-04
WO2000061169A1 (fr) 2000-10-19
NO20014893D0 (no) 2001-10-08
KR20020016770A (ko) 2002-03-06
EP1181036A1 (fr) 2002-02-27
CN1354669A (zh) 2002-06-19
JP2002541208A (ja) 2002-12-03
DK1181036T3 (da) 2008-11-24
ZA200109236B (en) 2003-12-08
PL351837A1 (en) 2003-06-16
CN1165339C (zh) 2004-09-08
CA2369444A1 (fr) 2000-10-19
NO20014893L (no) 2001-11-15
PL203797B1 (pl) 2009-11-30
ATE401908T1 (de) 2008-08-15
CY1108418T1 (el) 2014-04-09
IL145816A0 (en) 2002-07-25
BR0010665A (pt) 2004-03-09
US6696056B1 (en) 2004-02-24
HUP0201068A2 (en) 2002-08-28
AR029623A1 (es) 2003-07-10
HK1041445A1 (en) 2002-07-12
HUP0201068A3 (en) 2002-10-28
HK1041445B (en) 2009-07-03
US20040248797A1 (en) 2004-12-09
AU775041B2 (en) 2004-07-15
AU4218600A (en) 2000-11-14
ES2308978T3 (es) 2008-12-16
EP1181036B1 (fr) 2008-07-23
MXPA01010208A (es) 2003-07-21
EP1181036A4 (fr) 2004-04-21
CA2369444C (fr) 2009-08-18

Similar Documents

Publication Publication Date Title
BG106046A (en) Pharmaceutical compositions of ertythropoietin
US6136294C1 (en) Amino acid stabilized medical aerosol formulation
EP1166767A3 (fr) Produit pour le soin de la peau contenant de la hydroxypoline ou des dérivés de la N-acétyl hydroxyproline
AU7207098A (en) Stabilization of acid sensitive benzimidazols with amino acid/cyclodextrin combinations
PT1083884E (pt) Processo para a estabilizacao de composicoes de polivinil-pirrolidona
IL101348A0 (en) Polyethylene glycol protein conjugates,their preparation and pharmaceutical compositions containing them
BR0112094A (pt) Produtos de confeitaria contendo ingredientes ativos
AU1263400A (en) Stable aqueous insulin preparations without phenol and cresol
AU4073901A (en) Novel pharmaceutical or dietetic mushroom-based compositions
GR3007107T3 (fr)
IL115590A0 (en) Pharmaceutical formulation comprising a growth hormone and isoleucine
ZA200007415B (en) Amino acid derivatives and drugs containing the same as the active ingredient.
KR970706840A (ko) 성장호르몬 및 발린으로 이루어진 약학적 조성물(a pharmaceutical formulation comprising a growth hormone and valine)
MXPA03002807A (es) Estabilizacion de formulaciones solidas de farmacos.
WO1999067238A3 (fr) Agents antimicrobiens di- et tetra-hydroquinoline-indol, utilisations et compositions correspondantes
WO2002062304A3 (fr) Agents cosmetiques et/ou pharmaceutiques
CA2141961A1 (fr) Antioxydant
WO2001068676A3 (fr) Nouveaux antagonistes de la lhrh, sa production et son utilisation comme medicament
AU4609693A (en) An interferon-alpha/beta binding protein its preparation and pharmaceutical compositions containing it
MXPA02003731A (es) Derivados novedosos de acido fusidico.
AU5284999A (en) New injectable formulations containing ramoplanin
WO2001039725A3 (fr) Preparations de medicaments
RU98105720A (ru) Биологически активная добавка для лечебных и косметических средств
TH32452A (th) สารดับกลิ่น
CA2024642A1 (fr) Preparations pour usage externe contenant de l'eau